{"id":"W2120393706","doi":"10.1136/annrheumdis-2016-210715","title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","year":2017,"lang":"en","type":"review","venue":"Annals of the Rheumatic Diseases","topic":"Rheumatoid Arthritis Research and Therapies","field":"Medicine","cited_by":5775,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital","funders":"European League Against Rheumatism; National Institute for Health and Care Research","keywords":"Medicine; Abatacept; Adalimumab; Certolizumab pegol; Tocilizumab; Infliximab; Golimumab; Etanercept; Rituximab; Rheumatoid arthritis; Antirheumatic drugs; Rheumatism; Antirheumatic Agents; Intensive care medicine; Disease; Physical therapy; Internal medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null}